A TNM-Based Clinical Staging System of Ocular Adnexal Lymphomas

2009 ◽  
Vol 133 (8) ◽  
pp. 1262-1267 ◽  
Author(s):  
Sarah E. Coupland ◽  
Valerie A. White ◽  
Jack Rootman ◽  
Bertil Damato ◽  
Paul T. Finger

Abstract Context.—The ocular adnexal lymphomas (OAL) arise in the conjunctiva, orbit, lacrimal gland, and eyelids. To date, they have been clinically staged using the Ann Arbor staging system, first designed for Hodgkin and later for nodal, non–Hodgkin lymphoma. The Ann Arbor system has several shortcomings, particularly when staging extranodal non– Hodgkin lymphomas, such as OAL, which show different dissemination patterns from nodal lymphomas. Objective.—To describe the first TNM-based clinical staging system for OAL. Design.—Retrospective literature review. Results.—We have developed, to our knowledge, the first American Joint Committee on Cancer–International Union Against Cancer TNM-based staging system for OAL to overcome the limitations of the Ann Arbor system. Our staging system defines disease extent more precisely within the various anatomic compartments of the ocular adnexa and allows for analysis of site-specific factors not addressed previously. It aims to facilitate future studies by identifying clinical and histomorphologic features of prognostic significance. This system is for primary OAL only and is not intended for intraocular lymphomas. Conclusions.—Our TNM-based staging system for OAL is a user-friendly, anatomic documentation of disease extent, which creates a common language for multicenter and international collaboration. Data points will be collected with the aim of identifying biomarkers to be incorporated into the staging system.

Cancer ◽  
1973 ◽  
Vol 31 (1) ◽  
pp. 72-80 ◽  
Author(s):  
Robert R. Smith ◽  
Ralph Caulk ◽  
Edgar Frazell ◽  
Paul H. Holinger ◽  
William S. Maccomb ◽  
...  

2009 ◽  
Vol 33 (3) ◽  
pp. 289-295 ◽  
Author(s):  
A M Sharma ◽  
R F Kushner

Blood ◽  
1989 ◽  
Vol 74 (2) ◽  
pp. 551-557 ◽  
Author(s):  
WS Velasquez ◽  
S Jagannath ◽  
SL Tucker ◽  
LM Fuller ◽  
LB North ◽  
...  

Two hundred and fifty previously untreated adult patients with diffuse large-cell lymphomas were treated with a chemotherapy combination of cyclophosphamide, adriamycin, vincristine, prednisone, and low-dose bleomycin (CHOP-Bleo) with or without radiotherapy between 1974 and 1984. The 10-year survival rates for patients with Ann Arbor stages II, III, or IV disease of 55%, 42%, and 40%, respectively, were not significantly different. However, the survival rate of 76% for patients with stage I disease was clearly better. Factors more indicative of prognosis than stage, as found by univariant analysis, were tumor burden, serum lactic dehydrogenase level (LDH), age, and constitutional symptoms. From these, a multivariant analysis selected tumor burden, LDH level, and age as major independent factors for predicting survival (P less than .001). A prognostic risk model constructed on the basis of tumor burden and LDH levels identified four distinct risk groups (A, B, C, D) with 10-year survival rates of 85%, 66%, and 43% for A, B, and C. No patient in group D survived 10 years. These risk groups also had a strong correlation with complete remission rates and with relapse rates. Thus this model proved more effective for identifying patient populations according to their expected responses, durations of remission, and survivals than the Ann Arbor staging system. Detailed information supporting the use of this system for predicting prognosis and for treatment selection for patients with diffuse large-cell lymphomas is provided.


1984 ◽  
Vol 2 (2) ◽  
pp. 135-139 ◽  
Author(s):  
S S Donaldson ◽  
J A Belli

There is a need for a rational and useful staging system for childhood rhabdomyosarcoma that predicts prognosis based on the biology and natural history of the disease. Important factors to consider are age, histology, tumor volume, extent of invasion, and lymphatic involvement. A clinical staging system based on a classical tumor/node/metastasis status, and which accounts for natural history as a function of site of primary, local invasion, and lymphatic or hematogenous metastases is presented. This staging system eliminates the requirement that stage is assigned following an initial therapeutic strategy and removing the implication that prognosis is determined by that strategy.


Blood ◽  
1982 ◽  
Vol 60 (3) ◽  
pp. 571-577 ◽  
Author(s):  
J Jansen ◽  
J Hermans

Abstract To find a clinical staging system for patients with hairy cell leukemia, 391 patients contributed by 22 centers were analyzed using the proportional hazard survival model. Attention was paid to nonsplenectomized patients to find a staging system to predict the survival length at the time of diagnosis. On the basis of hemoglobin level and spleen size at the time of diagnosis, 3 stages could be distinguished with significantly different prognoses (stages I-III). In addition, we addressed the question of splenectomy to identify those patients who benefit from the operation. Using arbitrary, but clinically relevant, criteria to call the operation beneficial, splenectomy appears to be indicated for patients with large spleens (greater than or equal to 4 cm under costal margin) or with smaller, but palpable, spleens when anemia (Hb less than 12 g/dl) is present. The third question concerned the splenectomized patients. To indicate the patients who have a poor postsplenectomy survival, a staging system was developed on the basis of hemoglobin level and number of neutrophils at 2–3 mo after the operation (stages A-C). The validity of the two staging systems was supported by the results of an analysis of an independent test series of patients. These staging systems may be helpful for the choice of therapy and in the planning of clinical trials in patients with hairy-cell leukemia.


Cancer ◽  
2002 ◽  
Vol 95 (6) ◽  
pp. 1334-1345 ◽  
Author(s):  
Andrea Baur ◽  
Axel Stäbler ◽  
Dorothea Nagel ◽  
Rolf Lamerz ◽  
Reiner Bartl ◽  
...  

2004 ◽  
Vol 171 (3) ◽  
pp. 1246-1247
Author(s):  
Mark K. Buyyounouski ◽  
Eric M. Horwitz ◽  
Alexandra L. Hanlon ◽  
Robert G. Uzzo ◽  
Alan Pollack

Sign in / Sign up

Export Citation Format

Share Document